Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Cancer remains one of the most formidable challenges in modern medicine — but it is also one of the most dynamic frontiers of pharmaceutical innovation. Over the past decade, oncology has become the ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

A new study shows that combining laser treatment with immunotherapy significantly improves survival rates in patients with ...

While drugs like Keytruda are often described as breakthroughs, the study shows that their price places them far beyond the reach of the majority of patients who may need them.

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

A new study lays bare the crushing economics of cancer care, questioning whether modest survival gains justify staggering ...

A recent study highlights the effectiveness of adding a minimally invasive laser procedure to immunotherapy, significantly improving survival rates for patients with recurrent high-grade astrocytoma, ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...